Navigation Links
Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Date:9/11/2008

MONTVALE, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced findings from a study that indicated Synvista's proprietary monoclonal enzyme immunoassay can determine a person's haptoglobin pheno/genotype in less than two hours, and can aid physicians in predicting cardiovascular risk in patients with diabetes. The study was presented today at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland.

"This study shows the utility of our proprietary technology to diagnose Hp2-2 Diabetes, a disease affecting almost 7 million people in the United States," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that the ease of use of our haptoglobin diagnostic technology and rapid results bode well for its acceptance as an important tool in the treatment of cardiovascular disease in diabetic patients. In addition, we believe that the development of genetic markers like those identified by our test will continue to pave the way toward a personalized medicine model that will benefit a wider variety of patients in a more direct and reliably predictive manner."

In the study, investigators developed an ELISA (enzyme-linked immunosorbent assay) using a monoclonal antibody that differentiates between the three haptoglobin pheno/genotypes. Blood samples from diabetic patients with known haptoglobin pheno/genotypes were tested using Synvista's proprietary methodology. Results demonstrated 99.5% accuracy in determining each of the three haptoglobin types (48/48 Hp 1-1, 49/49 Hp2-1 and 90/91 Hp-2-2) with a greater than or equal to 98% sensitivity and specificity for each phenotype.

Additionally, a secon
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
2. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
3. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
4. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
5. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
6. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
7. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
8. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
9. Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
10. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Amgen (Nasdaq: AMGN ) announced today ... Medicines Agency (EMA) for a re-examination of the negative ... Products for Human Use (CHMP) for the use of Vectibix ... KRAS metastatic colorectal cancer (mCRC). Amgen ...
... SAN DIEGO, March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... City.   The live presentation takes place ... / 10:20 a.m. Pacific Time.  The presentation will be webcast ...
Cached Medicine Technology:Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 2Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 3Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 4Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 5Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 6Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 7Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 8Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 9
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... (OTC Bulletin Board: MACM) announced today that all ... converted their shares of preferred,stock into 12,571,850 shares ... shares of common stock previously issued with the ... 17,885,848 shares with an,exercise price of $.60 per ...
... Abbott has been named to,Hispanic Business magazine,s ... was recognized as one of the magazine,s "Diversity ... promotion, marketing,philanthropy and supplier diversity. "As an ... our,people to provide different ideas, perspectives and experience ...
... drink it daily lose less bone, study finds , , ... suggests that having a cuppa (tea, that is) may ... that drinking tea in moderation can actually benefit your ... in the nutrition program at the School of Exercise, ...
... For the first time,comprehensive information on long term ... it will be available from a single source: ... Today, LTC Financial,Partners (LTCFP), the nation,s most experienced ... CareScout, creator of the first,quality-of-care ratings on nursing ...
... Oct. 10 Adaptis, a leading provider of,Business ... has completed two company fundraising initiatives. One took ... the other in Yakima,Washington, where its regional operations ... way to involve Adaptis employees in goodwill,programs in ...
... may not have to get sick this flu,season. ... get your flu shot now.,But, not enough people ... deaths annually. Listen to this report from ... access video, audio, text, graphics and,photos for free ...
Cached Medicine News:Health News:MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement 2Health News:MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement 3Health News:Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine 2Health News:Tea Helps Toughen Older Women's Hips 2Health News:Tea Helps Toughen Older Women's Hips 3Health News:LTC Financial Partners (LTCFP) Engages CareScout to Bring Comprehensive Long Term Care Solutions to LTCFP Clients; A One-Stop Shop for All Care Information - An Industry First 2Health News:Adaptis Supports Local Yakima-Based YWCA and National Diabetes 2
...
... System is a complete anterior ... portable, it offers high-end performance ... console. It also provides all ... segment surgery. These include Irrigation, ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: